{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T20:52:06Z","timestamp":1761339126538},"reference-count":32,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,8,20]],"date-time":"2007-08-20T00:00:00Z","timestamp":1187568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Rectally administered mesalazine (mesalamine; 5\u2010aminosalicylic acid) is the first\u2010line therapy for treatment of distal ulcerative colitis. Recently, a high\u2010volume 5\u2010aminosalicylic acid foam has been shown to be as effective and safe as standard 5\u2010aminosalicylic acid enema.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To study the efficacy and safety of a low\u2010volume vs. a high\u2010volume 5\u2010aminosalicylic acid foam.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In this investigator\u2010blinded study, patients with active distal ulcerative colitis [Clinical Activity Index (CAI)\u2003&gt;\u20034, Endoscopic Index\u2003\u2265\u20034] were randomized to receive 2\u2003\u00d7\u20031\u2003g\/30\u2003mL low\u2010volume (<jats:italic>n\u2003<\/jats:italic>=\u2003163) or 2\u2003\u00d7\u20031\u2003g\/60\u2003mL high\u2010volume 5\u2010aminosalicylic acid foam (<jats:italic>n\u2003<\/jats:italic>=\u2003167) for 42\u2003days. Primary end point was clinical remission (CAI\u2003\u2264\u20034) at the final\/withdrawal visit (per\u2010protocol).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> 330 patients were evaluable for efficacy and safety by intention\u2010to\u2010treat, 290 for per\u2010protocol analysis. Clinical remission rates at week 6 (per\u2010protocol) were 77% on low\u2010volume foam vs. 77% on high\u2010volume foam (<jats:italic>P\u2003<\/jats:italic>=\u20030.00002 for non\u2010inferiority). The low\u2010volume foam was associated with a lower frequency of severe discomfort, pain and retention problems.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Low\u2010volume 5\u2010aminosalicylic acid foam is as effective and safe as a high\u2010volume 5\u2010aminosalicylic acid foam in the treatment of active distal ulcerative colitis, but offers compliance advantages compared to the high\u2010volume preparation.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2007.03468.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T08:07:33Z","timestamp":1279872453000},"page":"1237-1249","source":"Crossref","is-referenced-by-count":31,"title":["Clinical trial: randomized\u2010controlled clinical study comparing the efficacy and safety of a low\u2010volume vs. a high\u2010volume mesalazine foam in active distal ulcerative colitis"],"prefix":"10.1111","volume":"26","author":[{"given":"R.","family":"ELIAKIM","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"TULASSAY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"KUPCINSKAS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"ADAMONIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"POKROTNIEKS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"BAR\u2010MEIR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"LAVY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"MUELLER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"GREINWALD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"CHERMESH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"GROSS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ON BEHALF OF THE INTERNATIONAL SALOFALK FOAM STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,22]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.043372"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1017987229718"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.02.071"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-813510"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.40036.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.17.s2.3.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02048.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00384.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02180.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01940.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01199.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00784.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6666.82"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90621-4"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.2.174"},{"key":"e_1_2_7_17_2","first-page":"1188","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group","volume":"88","author":"Hanauer S","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.2307\/2531959"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.1999.01286.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.2307\/2530245"},{"volume-title":"ADDPLAN \u2013 Adaptive Designs, Plans and Analyses, Release 2.0","year":"2003","author":"ADDPLAN GmbH","key":"e_1_2_7_21_2"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091208"},{"key":"e_1_2_7_23_2","first-page":"283","volume-title":"Handbook of Sequential Analysis","author":"Jennison C","year":"1991"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02743.x"},{"key":"e_1_2_7_25_2","first-page":"677","article-title":"Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF\u20103 study group","volume":"31","author":"Ardizzone S","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.010"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.038505"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02861.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00248.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.060103"},{"key":"e_1_2_7_31_2","first-page":"525","article-title":"Relative bioavailability of mesalazine comparing different rectal formulations with oral delayed release granules","volume":"44","author":"Dilger K","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0269-2813.2004.01827.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-6687-x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03468.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03468.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T19:30:08Z","timestamp":1697225408000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03468.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,22]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03468.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03468.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"type":"print","value":"0269-2813"},{"type":"electronic","value":"1365-2036"}],"subject":[],"published":{"date-parts":[[2007,8,22]]}}}